PFL-721

PFL-721 (STX-721) is a small molecule kinase inhibitor from Antares Therapeutics, with Pierre Fabre Laboratories as licensee and Scorpion Therapeutics as partner. A mutant-specific inhibitor of EGFR exon 20 and HER2 exon 20 insertion mutations. Its furthest stage is phase 1, for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations. ClinicalTrials.gov registers it in one study linked below. First-in-human phase 1/2 NCT06043817 recruiting, sponsored by Pierre Fabre Medicament. Whether it works in people has not been established unless a trial below reports it.